Endoscopic internal drainage versus endoscopic vacuum therapy for upper gastrointestinal leaks: what's the real deal?
- PMID: 36538922
- DOI: 10.1055/a-1888-4116
Endoscopic internal drainage versus endoscopic vacuum therapy for upper gastrointestinal leaks: what's the real deal?
Conflict of interest statement
S. Danese has served as a speaker, consultant, and advisory board member for Schering-Plough, AbbVie, Actelion, Alphawasserman, AstraZeneca, Cellerix, Cosmo Pharmaceuticals, Ferring, Genentech, Grunenthal, Johnson and Johnson, Millenium Takeda, MSD, Nikkiso Europe GmbH, Novo Nordisk, Nycomed, Pfizer, Pharmacosmos, UCB Pharma and Vifor. The remaining authors declare that they have no conflict of interest.
Comment in
-
Reply to Danese et al.Endoscopy. 2023 Jan;55(1):101. doi: 10.1055/a-1901-8750. Epub 2022 Dec 20. Endoscopy. 2023. PMID: 36538923 No abstract available.
Comment on
-
Endoscopic internal drainage and low negative-pressure endoscopic vacuum therapy for anastomotic leaks after oncologic upper gastrointestinal surgery.Endoscopy. 2022 Jan;54(1):71-74. doi: 10.1055/a-1375-8151. Epub 2021 Apr 8. Endoscopy. 2022. PMID: 33506454
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources